Volume and price movement occurring yesterday and today!

News out today !

There is someone slowly buying a few hundred shares a day above .50!

Does anyone know what’s going on?

Getting some action on Qrons today!

12/14/22. New Pre-clinical Research program was announced !

We have had one trade per day for the last two consecutive days may be able trade today

This is coming to life!

Wow

2,276 @ .80 !

Traded to day
.50 and .51
No news

He's mentioned other reductions are possible.

HPIL: looks like they are trying!
606.34M OS. Reducing only AS?

Thank you
I’ll look
You might look at CYCA!

No i don't think i did call. I had forgotten about this one until you pulsed. Let me look at it again in the AM. In the meantime you might find a good one in HPIL. Still bargain prices there

Traded today 200 shares

Did you follow through with this?

I wonder what their funding source is or if they are going to file for 2020 soon. Maybe I will call and ask.

This look like a fun little stock. I don't want to buy in after the jump though. I'd like it a little cheaper. Your thoughts?

Anyone still here, or own this?! Nice share structure, popped over 100% today, but on tiny volume...

PR a month ago about developing "next generation treatments for unmet neuronal diseases, using tissue engineering, stem cells and machine learning synergic technologies"....

Big EOD dump to .36... $QRON

Getting some volume and interest here today... $QRON

Uplisting news is going to hit soon. IMO

From and after the occurrence of an Exit Event, as such term is described in the Royalty Agreement, including an underwritten public offering of the Company’s shares with proceeds of at least $25 million, a consolidation, merger or reorganization of the Company, and a sale of all or substantially all of the shares and/or the assets of the Company, Ariel has the right to require the Company to issue up to 3% of the issued and outstanding shares of common stock of the Company at the time Ariel exercises such right.

$QRON

Very unique opportunity to get involved in a biotech with great opportunity to make a nice profit.If they can do in people what they do in mice this is a grand slam

NO SUBSTANCE AT ALL ....JUST BS ..BAIL WHEN YOU GET THE CHANCE ON THIS POS OR SHORT

Qrons Inc.’s Jonah Meer Joins Everett Jolly on the Stock Day Podcast (QRON) November 5, 2019.

About Qrons Inc.

Headquartered in New York City, Qrons is a publicly traded emerging biotechnology company developing advanced stem cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries and concussions. The Company has two product candidates for treating TBIs, both integrating proprietary, modified mesenchymal stem cells (“MSCs”) and smart synthetic material, QS100™, an injury specific, 3D printable, implantable MSCs-synthetic hydro gel, to treat penetrating brain injuries and QS200™, an inject able Ms Cs-synthetic hydro gel for the treatment of diffused injuries commonly referred to as concussions.

The Company is a party to a license and research funding agreement and related service agreements with Ariel Scientific Innovations Ltd., a wholly owned subsidiary of Ariel University, based in Ariel, Israel, and in addition to the world-wide exclusive intellectual property license, a Sponsored Research Agreement with Dartmouth College funding further research with Professor Chenfeng Ke and his team in the Chemistry Department, to develop innovative 3D printable, bio-compatible advanced materials. For additional information, please visit www.qrons.com.

LINK: https://stockdaymedia.com/news/radio-interviews/qrons-inc-s-jonah-meer-joins-everett-jolly-on-the-stock-day-podcast-qron-november-5-2019/

$QRON

Qrons Extends Sponsored Research Agreement with Dartmouth College

Supports Continued Research for the Development of Innovative 3D Printable, Biocompatible Advanced Materials, and Stem Cell Delivery Techniques for Traumatic Brain Injuries

NEW YORK, NY, Nov. 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Qrons Inc. (OTCQB: QRON), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions for the treatment of traumatic brain injuries (TBIs) including concussions and penetrating injuries, today announced that it has extended the term of its Sponsored Research Agreement with Dartmouth College for an additional year with funding through July 14, 2020.

Professor Chenfeng Ke of the Chemistry Department at Dartmouth, and a member of the Qrons Scientific Advisory Board, will continue as the Principal Investigator for the sponsored research. Since July 2018, Qrons has been conducting research with Professor Ke to develop innovative 3D printable, biocompatible advanced materials as a component of its stem cell-based TBI treatment. In October 2019, Qrons entered into an Intellectual Property License Agreement with Dartmouth for an exclusive world-wide license of intellectual property related to 3D printable materials in the fields of human and animal health. Professor Ke is also an inventor of the licensed 3D process.

Professor Chenfeng Ke commented, “Our project plan for the next year includes exploring a deeper level of integration of our hydrogels with cells and the surrounding environment to expand their adaptability for biomedical applications.”

Jonah Meer, Qrons' co-founder and CEO, added, "The extension of the Sponsored Research Agreement is a testament to the working relationship of our teams and the important work we’re doing together to improve the treatment of TBIs.”

"The importance of continuing our research with the team at Dartmouth cannot be overstated. We value our working relationship and are confident that we will continue to advance towards achievement of our goals,” concluded Ido Merfeld, Qrons’ co-founder, President and Head of Product.

About Dartmouth College

Founded in 1769, Dartmouth College is a member of the Ivy League and consistently ranks among the world's greatest academic institutions. Dartmouth has forged a singular identity for combining its deep commitment to outstanding undergraduate liberal arts and graduate education with distinguished research and scholarship in the Arts & Sciences and its three leading professional schools - the Geisel School of Medicine, Thayer School of Engineering, and the Tuck School of Business.

About Qrons Inc.

Headquartered in New York City, Qrons is a publicly traded emerging biotechnology company developing advanced stem cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries and concussions. The Company has two product candidates for treating TBIs, both integrating proprietary, modified mesenchymal stem cells ("MSCs") and smart synthetic material, QS100™, an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200™, an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions. For additional information, please visit www.qrons.com.

Forward Looking Statement

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.

Contacts:
Qrons Inc.
Jonah Meer
Chief Executive Officer
212-945-2080

Stephanie Prince
PCG Advisory
sprince@pcgadvisory.com
646-762-4518

LINK: http://www.globenewswire.com/news-release/2019/11/11/1944687/0/en/Qrons-Extends-Sponsored-Research-Agreement-with-Dartmouth-College.html

$QRON

Qrons is Developing 3D Printable Implants to Treat Brain Injuries

October 18, 2019 - by Vanesa Listek - 3D Printing - 3D Printing Materials - Medical 3D Printing

Every year traumatic brain injuries (TBI) affect an average of 69 million individuals worldwide. Although the number is less than one percent of the total global population, it is large enough to draw attention from researchers and companies trying to ease the pain and suffering related to the injury, which is usually the result of a fall, a sports injury and especially traffic accidents. In the United States, it is one of the leading causes of death and disability among children and young adults. With so many biotechnology companies springing up to resolve, via bioprinting, many common afflictions and diseases, one of them has been developing advanced stem cell-based solutions since 2016 to combat neuronal injuries, with a particular focus on TBI and concussions.

Qrons, headquartered in New York, is now going further with their innovative research after they announced an agreement with Dartmouth College, in New Hampshire, for an exclusive worldwide license to develop innovative 3D printable biocompatible materials to treat penetrating brain injuries, and more.

The agreement, signed October on 2, allows Qrons to use a patented 3D process entitled Mechanically Interlocked Molecules-based Materials for 3D Printing as part of its injury-specific 3D printable implants to treat penetrating brain injuries. Qrons is also a funding party to a sponsored research agreement with Dartmouth to advance the license or ownership of additional intellectual property, and the company’s research team is already working closely with Chenfeng Ke, the inventor of the licensed 3D process and an Assistant Professor at the university’s Department of Chemistry, to develop innovative 3D printable, biocompatible advanced materials.

Chenfeng Ke is currently leading the Ke Functional Materials Group Lab at Dartmouth, which focuses on syntheses and applications of polymeric materials for storage/separation and 3D printing applications. According to the lab, the research scheme overlaps organic synthesis, crystal engineering, polymer synthesis, materials characterization, and 3D printing, with an emphasis on the design of polymeric materials that are noncovalently assembled.

Qrons Inc. (OTCQB: QRON) | SNN Network

Qrons Granted Exclusive World-Wide License by Dartmouth College for Intellectual Property Related to 3D Printable Materials in Human and Animal Health

Qrons is Developing 3D Printable Implants to Treat Penetrating Brain Injuries

NEW YORK, NY, Oct. 14, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Qrons Inc. (OTCQB: QRON), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions for the treatment of traumatic brain injuries, including concussions and penetrating injuries, announced today that it has entered into an Intellectual Property License Agreement (the “Agreement”) with Dartmouth College for an exclusive world-wide license of Intellectual Property related to 3D printable materials in the fields of human and animal health. The Agreement provides for the payment by Qrons of initial and annual license fees and royalty payments based upon Qrons' product sales. The Agreement was signed on October 2, 2019 and is effective as of September 3, 2019.

Qrons is using the 3D process covered by the patent entitled “Mechanically Interlocked Molecules-based Materials for 3D Printing” as part of its injury specific 3D printable implants to treat penetrating brain injuries. Qrons is also a party to a Sponsored Research Agreement with Dartmouth to advance the license or ownership of additional Intellectual Property. The Qrons research team is working closely with Professor Chenfeng Ke, a member of Qrons Scientific Advisory Board and an inventor of the licensed 3D process, and PhD candidate Qianming Lin.

Ido Merfeld, Qrons Co-founder and Head of Product, commented, “The intellectual property covered by this license has been instrumental in helping us advance our research on the treatment of penetrating brain injuries. We believe combining Qrons’ proprietary hydrogel with customizable 3D printing capabilities is an innovative approach to treating traumatic brain injuries, for which there are limited treatments.”

Jonah Meer, Qrons’ Co-founder and CEO, added, “We’re excited to have concluded negotiations to acquire an exclusive license for this important intellectual property. There is a great need for our promising treatments, and this technology is an integral part of our work to develop innovative 3D printable, biocompatible advanced materials.”

Chenfeng Ke, Assistant Professor of Chemistry, Dartmouth College, stated, “We are excited to partner with Qrons and continue the development of smart hydrogels with 3D printing capability for the treatment of traumatic brain injuries.”

Nila Bhakumi, Director of Technology Transfer at Dartmouth, echoed Professor Ke’s comments and added, “We are delighted with Dr. Ke’s collaboration with Qrons as they try to solve the very important problem of Traumatic Brain Injury.”

About Dartmouth College

Founded in 1769, Dartmouth College is a member of the Ivy League and consistently ranks among the world's greatest academic institutions. Dartmouth has forged a singular identity for combining its deep commitment to outstanding undergraduate liberal arts and graduate education with distinguished research and scholarship in the Arts & Sciences and its three leading professional schools - the Geisel School of Medicine, Thayer School of Engineering, and the Tuck School of Business.

About Qrons Inc.

Headquartered in New York City, Qrons is a publicly traded emerging biotechnology company developing advanced stem cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries and concussions. The Company has two product candidates for treating TBIs, both integrating proprietary, modified mesenchymal stem cells ("MSCs") and smart synthetic material, QS100™, an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200™, an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions.

The Company is a party to a license and research funding agreement and related service agreements with Ariel Scientific Innovations Ltd., a wholly owned subsidiary of Ariel University, based in Ariel, Israel, and in addition to the world-wide exclusive intellectual property license, a Sponsored Research Agreement with Dartmouth College funding further research with Professor Chenfeng Ke and his team in the Chemistry Department, to develop innovative 3D printable, biocompatible advanced materials. For additional information, please visit www.qrons.com.

Forward Looking Statement

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.

Contacts:

Qrons Inc.
Jonah Meer
Chief Executive Officer
212-945-2080

Stephanie Prince
PCG Advisory
sprince@pcgadvisory.com
646-762-4518

LINK: https://www.globenewswire.com/news-release/2019/10/14/1929119/0/en/Qrons-Granted-Exclusive-World-Wide-License-by-Dartmouth-College-for-Intellectual-Property-Related-to-3D-Printable-Materials-in-Human-and-Animal-Health.html

$QRON

Huge 8-K today for exclusive Dartmouth patent rights. $QRON

Qrons Announces Appointment of Derrick Chambers to Advisory Board

Sep 23, 2019 8:00 AM EDT

Former NFL Player is Financial Literacy Advocate to NFL Players Association and NFL Alumni Association

NEW YORK, NY, Sept. 23, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Qrons Inc. (OTCQB: QRON), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions for the treatment of traumatic brain injuries (“TBI”), including concussions and penetrating injuries, today announced that Derrick Chambers has been appointed to the Company’s Advisory Board, effective immediately.

Derrick Chambers, a former National Football League (“NFL”) defensive lineman for 3 years with the Carolina Panthers and the Jacksonville Jaguars, is a member of the National Football League Players Association and Alumni Association where he provides financial literacy and advisory services for professional athletes and entertainers. After the NFL, Mr. Chambers studied at the University of Oxford in England and at Oriel College Oxford. He continued his studies at the Princeton Theological Seminary, where he served as an Academic-Athletic fellow mentoring student athletes. He currently serves as a Board member of the Youth Leadership Foundation of Washington, D.C.

“We welcome Derrick Chambers to the Advisory Board of Qrons. Given his background as an NFL player and current role with the Players and Alumni Associations, he is acutely aware of the potential for Chronic Traumatic Encephalopathy, a progressive degenerative disease of the brain that results from repetitive concussions and is often found in longtime players of the sport. We look forward to his contributions and insight and his help raising awareness of Qrons’ potential for the treatment of traumatic brain injuries,” said Jonah Meer, CEO of Qrons.

Derrick Chambers added, “I believe that Qrons’ two product candidates have the potential to help the many chronic suffers of TBIs, a serious and degenerative condition that has no approved products for treatment. This is important work and I’m happy to join with them to raise awareness among my former colleagues and the community at large.”

About Qrons Inc.

Headquartered in New York City, Qrons is a publicly traded emerging biotechnology company developing advanced stem cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries and concussions. The Company has two product candidates for treating TBIs, both integrating proprietary, modified mesenchymal stem cells (“MSCs”) and smart synthetic material, QS100™, an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200™, an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions. The Company is a party to a license and research funding agreement and related service agreements with Ariel Scientific Innovations Ltd., a wholly owned subsidiary of Ariel University, based in Ariel, Israel, and a Sponsored Research Agreement with Dartmouth College funding further research with Professor Chenfeng Ke and his team in the Chemistry Department, to develop innovative 3D printable, biocompatible advanced materials. The Company has negotiated a worldwide, royalty-bearing, exclusive license with Dartmouth for Professor Ke's 3D printable materials in the field of human and animal health. For additional information, please visit http://www.qrons.com.

Forward Looking Statement

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.


Contacts:

Qrons Inc.
Jonah Meer
Chief Executive Officer
212-945-2080

Stephanie Prince
PCG Advisory
sprince@pcgadvisory.com
646-762-4518

LINK: https://www.morningstar.com/news/globe-newswire/7720505/qrons-announces-appointment-of-derrick-chambers-to-advisory-board

$QRON

Qrons seeking to find a cure for traumatic brain injuries using a 3D-printable scaffold

2019-09-17 14:36:00 Christine Corrado

ONLY Company working on the regeneration of normal brain function through neural network regeneration.

https://s3.amazonaws.com/content.otcmarkets.com/media/599608008/hEQdqIEgwmbELoB/doc.pdf

$QRON

Qrons to Present at the RHK Capital 4th Annual Disruptive Growth Conference Hosted by ReedSmith

Presentation on Thursday, September 5, 2019 at 9:00am EST

NEW YORK, NY, Aug. 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Qrons Inc. (OTCQB: QRON), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions for the treatment of traumatic brain injuries, including concussions and penetrating injuries, announced today that it will be presenting at the 4th annual Disruptive Growth Conference on Thursday, September 5th at 9:00am EST. Jonah Meer, CEO, and John Bonfiglio, COO, will be presenting as well as meeting with investors.

The 2019 Disruptive Growth Conference will offer the exclusive opportunity to discover growth companies with disruptive technologies and business models covering the following sectors: communications, consumer, energy/alternative energy, healthcare, industrial, life sciences, natural resources, and technology.

For those interested in attending, please visit www.DisruptNYC.com for more information.

About Qrons Inc.

Headquartered in New York City, Qrons is a publicly traded emerging biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries and concussions. The Company has two product candidates for treating TBIs, both integrating proprietary, modified mesenchymal stem cells (“MSCs”) and smart synthetic material, QS100™, an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200™, an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions. The Company entered into a license and research funding agreement and related service agreements with Ariel Scientific Innovations Ltd., a wholly owned subsidiary of Ariel University, based in Ariel, Israel under which the Company received an exclusive worldwide royalty-bearing license in Ariel patents and know-how to develop and commercialize products for neuronal tissue regeneration and/or repair, resulting from Ariel's research or technology or the Company's research funding. The Company entered into a Sponsored Research Agreement with Dartmouth College funding further research with Professor Chenfeng Ke and his team in the Chemistry Department, to develop innovative 3D printable, biocompatible advanced materials. The Company is negotiating a worldwide, royalty-bearing, exclusive license with Dartmouth for Professor Ke's 3D printable materials in the field of human and animal health. For additional information, please visit http://www.qrons.com.

About RHK Capital:

Advisory Group Equity Services, Ltd. (dba RHK Capital) was founded in 1984. RHK Capital is a boutique investment banking firm specializing in small to medium-sized transactions. RHK is led by a management team with extensive financial industry experience and a desire to provide companies and individuals with the tools and expertise to accomplish their financial goals. In addition to investment banking, RHK has grown to include businesses in general securities, emerging market securities, distressed and high yield debt securities, investment management, mortgages, and business lending. As a division of Advisory Group Equity Services (AGES), all securities are offered through Advisory Group Equity Services Ltd., a registered broker-dealer, member of the Financial Industry Regulatory Authority and the Securities Investor Protection Corporation.

About TAG Group:

TAG is part of the holding company TAG Group, Inc., a leading provider of estate, business and financial services for high net worth individuals and business entities. TAG maintains a comprehensive network of legal, financial and accounting professionals who are committed to providing the highest level of service to their clients. TAG maintains three separate and distinct operating units under its corporate umbrella, they are: Trust Advisory Group, Ltd., Advisory Group Equity Services, Ltd., and Estate Insurance Services, Ltd.

About Reed Smith:

Reed Smith is a dynamic international law firm dedicated to helping clients move their businesses forward. Our long-standing relationships and international outlook make us the go-to partner for speedy resolution of complex transactions, disputes and regulatory matters. At Reed Smith, we believe that the practice of law has the ability to drive progress. We know your time is valuable and your matters are important. We are focused on outcomes, are highly collaborative, and have deep industry insight that, when coupled with our local market knowledge, allows us to anticipate and address your needs. You deserve purposeful, highly engaged client service that drives progress for your business.

Contacts:
Qrons Inc.
Jonah Meer
Chief Executive Officer
212-945-2080

Stephanie Prince
PCG Advisory
sprince@pcgadvisory.com
646-762-4518

LINK: https://www.globenewswire.com/news-release/2019/08/26/1906474/0/en/Qrons-to-Present-at-the-RHK-Capital-4th-Annual-Disruptive-Growth-Conference-Hosted-by-ReedSmith.html

$QRON

RHK Capital Presents 2019 Disruptive Growth Conference
http://disruptnyc.com

$QRON

Ground breaking breakthroughs happening. So happy I am along for the ride.

Solid company with a bright future. It’s exciting to watch the development of the future of treatment of traumatic brain injury‘s.

Qrons Selects PCG Advisory for Investor Relations and Strategic Communications as it Advances its Product Candidates

NEW YORK, NY,, Aug. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Qrons Inc. (OTCQB: QRON), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions for the treatment of traumatic brain injuries, including concussions and penetrating injuries, announced today that it has retained PCG Advisory Inc., a leading investor relations and digital strategies firm, to provide investor relations, strategic communications and capital market advisory services.

Jonah Meer, Qrons' Chief Executive Officer, commented, "Qrons has developed two product candidates based on innovative technology using 3D printable, biocompatible advanced materials and a novel delivery system to reduce neuronal loss and functional impairment and induce neuronal regeneration and functional improvement in the treatment of traumatic brain injuries. We have also recently appointed Dr. John Bonfiglio as Chief Operating Officer to oversee our IND process in preparation for human clinical trials. We believe that PCG’s seasoned team, contacts, skills and strategies will assist us in communicating these important advancements to investors.”

Jeff Ramson, CEO of PCG Advisory, said; “Qrons’ work is important as there are currently no approved treatment options for traumatic brain injuries. Supported by the upgrade of Qrons’ common stock to the OTCQB Venture Market, we look forward to working with QRON to raise their awareness and visibility within the investment community.”

About Qrons Inc.

Headquartered in New York City, Qrons is a publicly traded emerging biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries and concussions. The Company has two product candidates for treating TBIs, both integrating proprietary, modified mesenchymal stem cells (“MSCs”) and smart synthetic material, QS100™, an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200™, an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions. The Company entered into a license and research funding agreement and related service agreements with Ariel Scientific Innovations Ltd., a wholly owned subsidiary of Ariel University, based in Ariel, Israel under which the Company received an exclusive worldwide royalty-bearing license in Ariel patents and know-how to develop and commercialize products for neuronal tissue regeneration and/or repair, resulting from Ariel's research or technology or the Company's research funding. The Company entered into a Sponsored Research Agreement with Dartmouth College funding further research with Professor Chenfeng Ke and his team in the Chemistry Department, to develop innovative 3D printable, biocompatible advanced materials. The Company is negotiating a worldwide, royalty-bearing, exclusive license with Dartmouth for Professor Ke's 3D printable materials in the field of human and animal health. Please visit http://www.qrons.com.

About PCG Advisory Inc.

Founded in 2008, PCG Advisory is dedicated to the delivery of top-tier strategic advisory services that encompass investor and stakeholder relations, capital markets navigation, corporate communications and social media management for emerging growth companies. The team at PCG has extensive experience with life science, fintech and blockchain technology and works with innovative and emerging companies from around the globe. As an aggregation, distribution, and engagement platform, PCG reaches thousands of individual, retail and institutional investors and stakeholders in its proprietary and extensive distribution network, and through the use of unique digital marketing and audience development techniques. For more information, go to: www.pcgadvisory.com

Forward Looking Statement

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.

Contacts:

Qrons Inc.

Jonah Meer

Chief Executive Officer

212-945-2080



Stephanie Prince

PCG Advisory

sprince@pcgadvisory.com

646-762-4518

LINK: https://www.globenewswire.com/news-release/2019/08/19/1903508/0/en/Qrons-Selects-PCG-Advisory-for-Investor-Relations-and-Strategic-Communications-as-it-Advances-its-Product-Candidates.html

$QRON

Request for Project Information (RPI)

“Candidate Drug Treatment for Traumatic Brain Injury for Phase 2 Clinical Trials”

https://mtec-sc.org/wp-content/uploads/2019/08/19-11-TBI-DT_RPI_FINAL.pdf

$QRON

In the last session before lunch We learned about exciting commercialization efforts in AM from Drs Nancy Zhang
@Carbon, Nicolynn Davis @MilliporeSigma, and Ido Merfeld (QRons) #3DP19

In the last session before lunch We learned about exciting commercialization efforts in AM from Drs Nancy Zhang @Carbon, Nicolynn Davis @MilliporeSigma, and Ido Merfeld (QRons) #3DP19 pic.twitter.com/jOy7lJxEDs

— 3DP2019 (@3DPrinting_2019) August 13, 2019

Our first session also included a talk from the Qrons student travel award winner, Jia En Aw from the Sottos Lab @Illinois_Alma on an innovative direct write printing process that prints and cures all at once! #3DP19

Our first session also included a talk from the Qrons student travel award winner, Jia En Aw from the Sottos Lab @Illinois_Alma on an innovative direct write printing process that prints and cures all at once! #3DP19 pic.twitter.com/w1493Wa4cu

— 3DP2019 (@3DPrinting_2019) August 13, 2019

https://pcgadvisory.com/news/qrons-appoints-veteran-u-s-based-biotech-executive-dr-john-n-bonfiglio-to-lead-ind-and-capital-markets-related-activities/

$QRON

Qrons Announces Upgrade to OTCQB Market

Trading Continues Under Ticker "QRON"

NEW YORK, NY, Aug. 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Qrons Inc. (OTCQB: QRON) an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions for the treatment of traumatic brain injuries, including concussions and penetrating injuries, announced today that its common stock commenced trading today on the OTCQB Venture Market (OTCQB) after successfully upgrading from the Pink Market.

While Qrons has been a fully reporting company since its inception, the Company believes that the move to OTCQB will provide investor benefits including enhanced reporting standards, greater access to analyst coverage and news services, management certification and more comprehensive compliance requirements.

Jonah Meer, Qrons' Chief Executive Officer, commented, "We anticipate that the broader exposure afforded by the OTCQB Venture Market will raise our visibility within the investment community, assist in increasing the liquidity of our common stock and help to broaden our shareholder base. Upgrading to OTCQB is a significant milestone for any company, as it provides shareholders and potential investors with greater transparency and liquidity and will help generate exposure of our company to institutional investors.”

The OTCQB is a venture market designed for early-stage and developing US and international companies. To be eligible, companies must be current in their reporting and undergo an annual verification and management certification process. To learn more, visit OTCQB at www.otcmarkets.com

About Qrons Inc.

Headquartered in New York City, Qrons is a publicly traded emerging biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries and concussions. The Company has two product candidates for treating TBIs, both integrating proprietary, modified mesenchymal stem cells (MSCs) and smart synthetic material, QS100™, an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200™, an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions. The Company entered into a license and research funding agreement ("License Agreement") and related service agreements with Ariel Scientific Innovations Ltd., a wholly owned subsidiary of Ariel University, based in Ariel, Israel. In consideration for payments under the License Agreement, the Company received an exclusive worldwide royalty-bearing license in Ariel patents and know-how to develop and commercialize products for neuronal tissue regeneration and/or repair, resulting from Ariel's research or technology or the Company's research funding. The Company entered into a Sponsored Research Agreement with Dartmouth College funding further research with Professor Chenfeng Ke and his team in the Chemistry Department, aiming to develop innovative 3D printable, biocompatible advanced materials. The Company is negotiating a worldwide, royalty-bearing, exclusive license with Dartmouth for Professor Ke's 3D printable materials in the field of human and animal health. Please visit http://www.qrons.com.

Forward Looking Statement

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.

Contact:
Qrons Inc.
Jonah Meer
Chief Executive Officer
212-945-2080

LINK: https://www.globenewswire.com/news-release/2019/08/12/1900435/0/en/Qrons-Announces-Upgrade-to-OTCQB-Market.html

$QRON

OTC Markets Group Welcomes New OTCQB Companies – August 12

OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the following company is approved for trading on the OTCQB Venture Market:

Qrons Inc. (OTCQB: QRON) The Company is an emerging biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries (TBIs) and concussions. The Company has two product candidates for treating TBIs, both integrating proprietary, modified mesenchymal stem cells (MSCs) and smart synthetic material, QS100 an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200 an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions. The Company conducts its research in Israel under service agreements with Ariel University and has an ongoing Sponsored Research Agreement with Dartmouth College.

U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for this company on www.otcmarkets.com.

About OTC Markets Group Inc.

OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX Best Market, the OTCQB Venture Market and the Pink Open Market for 10,000 U.S. and global securities. Through OTC Link ATS and OTC Link ECN, we connect a diverse network of broker-dealers that provide liquidity and execution services. We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

OTC Link ATS and OTC Link ECN are SEC regulated ATSs, operated by OTC Link LLC, member FINRA/SIPC.

OTC Markets, OTCQX, OTCQB, Pink and OTC Link are registered trademarks of OTC Markets Group Inc.

LINK: http://www.publicnow.com/view/0617024D574B54204DE3C84EB7E98906238B7D71

$QRON

Dartmouth Launches Major Conference on 3D Printing’s Future

August 07, 2019

by Bill Platt

The gathering explores soft robotics, high-performance materials, and more.

Next week, Dartmouth will host one of the first international, interdisciplinary conferences on the future of “additive manufacturing,” the rapidly evolving field of 3D printing using advanced materials to create a spectrum of objects, such as artificial knee tendons, an implantable framework for brain neuron repair, soft-tissue robots, and performance-enhancing sneaker soles.

Assistant Professor of Chemistry Chenfeng Ke, an organizer of the conference, notes a certain kinship between this conference and the 1956 Dartmouth conference at which the term “artificial intelligence” was coined. The AI conference, like the upcoming 3D printing conference, was a gathering of the research community in a field on the cusp of new realms of discovery.

“The AI concept was cultivated here, so yes, in a similar way we want to cultivate some interdisciplinary collaborative thoughts in the area of additive manufacturing—AM,” Ke says. He hopes the symposium can become a regular event held every two years.

The two-day conference, to be held at the Hanover Inn Aug. 12 and 13, brings together researchers and scholars from the fields of chemistry, materials science, computer science, and engineering as well as industry players and entrepreneurs from across the United States, Europe, and Asia for “3D Printing 2019: An Interdisciplinary Additive Manufacturing Symposium.” Participants will look at a range of ideas in the field, including materials development, polymer chemistry, computational tools and models, green 3D printing, and 3D entrepreneurship. The talks and events on Monday afternoon, including a poster session and industry demonstration, are open to the public.

Until now, researchers in mechanical engineering, polymer and materials chemistry, computer science, and related fields have conferred separately to discuss 3D printing research, Ke says.

“There are separate meetings, but they don’t have cross talk, so we wanted to create this meeting to bring people with different expertise together, trying to connect from the very beginning—from the earliest computation and simulation, to the end-part of materials making and engineering,” Ke says.

The biomedical, printing materials, 3D printing technology, and 3D manufacturing industries as well as major publishing houses in the field are co-sponsors of the conference along with Dartmouth. Top scholars and researchers will make presentations at the conference, which will also include panel discussions and opening and closing sessions. In addition to Ke, the conference is co-chaired by Assistant Professor of Computer Science Bo Zhu, Adjunct Assistant Professor of Engineering Jeremy Faludi, and from the University of Texas at Dallas, Associate Professor of Chemistry Ronald Smaldone.

Ke’s own research uses carbohydrate-based printing materials he developed to create a tiny 3D architecture that can exist symbiotically with biological organisms on the cellular level. His lab is developing this material to enable 3D printing of structures such as artificial tissue scaffolds for treatment in traumatic brain injury.

“There are a lot of things you can play with in 3D printing, so that’s why we hope to inspire the different people who have different specialties and try to bring them together,” Ke says.

William Platt can be reached at william.c.platt@dartmouth.edu.

Bid moved up to $1.50... $QRON

5000 share bid @ $1.49... $QRON

Developing Treatments for Traumatic Brain Injuries (TBIs)
https://www.angelmd.co/en/startups/qrons-inc

Product Overview
We have two products candidates for treating TBIs, both integrating proprietary, modified mesenchymal stem cells (“MSCs”) and smart synthetic material. QS100TM is an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200TM is an injectable MSCs-synthetic

PRODUCT SNAPSHOT
Product Status: Prototype Complete
Clinical Trials: Pre-Clinical
Patents: Provisional
Market Size: $5B

COMPETITIVE ADVANTAGE
We believe we are the only Company working on a treatment for TBI. Other companies are working on detection systems, but not treating the TBI.

$QRON

Qrons Co-Founder Product & Science Introduction

OTCQB Certification filed 07/31/2019
https://backend.otcmarkets.com/otcapi/company/financial-report/226430/content

$QRON

Qrons Inc. SRO List Detail
https://www.accessdata.fda.gov/scripts/SDA/sdDetailNavigation.cfm?sd=srolist&id=8DBFA0F7FE0E1613E053564DA8C0BC5A&rownum=2457

Significantly Regulated Organizations (SROs)

HHS Supplemental Standards of Ethical Conduct formally defines SRO as “an organization for which the sales of products regulated by the Food and Drug Administration (FDA) constitute ten percent or more of annual gross sales in the organization's previous fiscal year; where an organization does not have a record of sales of FDA-regulated products, it will be deemed to be significantly regulated if its operations are predominately in fields regulated by FDA, or if its research, development, or other business activities are reasonably expected to result in the development of products that are regulated by FDA." See 5 C.F.R. § 5501.101(c)(2).

$QRON

Symposium of 3D Printing 2019
An Interdisciplinary Additive Manufacturing Symposium
August 12-13, 2019
Dartmouth College
Hanover, New Hampshire
https://3d-printing-2019.org

$QRON